Effect of Naproxen, Aspirin, Celecoxib, or Clopidogrel on the Healing of Stomach and Intestinal Ulcers - Trial NCT00778193
Access comprehensive clinical trial information for NCT00778193 through Pure Global AI's free database. This Phase 4 trial is sponsored by Research Associates of New York, LLP and is currently Completed. The study focuses on Gastroduodenal Ulcer. Target enrollment is 125 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Research Associates of New York, LLP
Timeline & Enrollment
Phase 4
Oct 01, 2007
Mar 01, 2008
Summary
Gastroduodenal ulcers are extremely common in the community today. Though much has been
 written and observed concerning how ulcers form, not much has been described in the human
 model concerning how these ulcers heal. As numerous patients already suffer from
 gastrointestinal ulcers, further clarification of ulcer healing would be valuable in the
 treatment and management of these patients. The goal of this study is to investigate the
 effects of naproxen, aspirin, celecoxib, and clopidogrel on biopsy-induced gastroduodenal
 lesions in order to elucidate the mechanisms of ulcer healing. This single site,
 single-blind, randomized, placebo-controlled, one-week prospective study will examine ulcer
 healing through endoscopic, immunohistologic, and molecular PCR modalities.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT00778193
Non-Device Trial